Recently, it has been reported that the administration of monoclonal antibodies against PCSK9 not only improves lipid profiles, but also beneficially alters inflammatory status and pulse wave velocity (PWV) in HeFH patients [40], although a significant reduction in PWV after a six-month PCSK9 inhibitor treatment was observed in FH subjects with a low neutrophil to lymphocyte ratio, indicating the higher inflammatory burden associated with atherosclerosis [41]. Here, PCSK9 is linked to atherosclerosis.